1. Scrip
  2. >>Focus On Asia

43 Pharmas Apply To Make Generics Of Off-Patent Plavix In China

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drug Plavix, whose patent expired in May.

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drugPlavix (clopidogrel), whose patent expired in May. Fifteen companies have gained approvals, including nine API makers (including Shenzhen Salubris Pharmaceutical Co., Ltd.) and two formulation producers (including Henan XInShuaike Pharmaceutical Co., Ltd.). According to SFDA figures, Plavix sales growth subdued from 65.7% in 2007 to 22% in 2011, and sales will likely reach RMB 20 billion in 2015, from RMB 6.8 billion in 2010. Looking forward, the drug will face competition from the increasingly prominent Taijia (clopidogrel) manufactured by Shenzhen Salubris, whose market share grew from 9.2% to 26.69% during 2006-2011, and other upcoming generics. (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Focus On Asia

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.